A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Abstract
Context: Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects—for instance, within a few hours or days—would have an enormous impact on patient care and public health.
Objective: To determine whether an N-methyl-Daspartate–receptor antagonist produces rapid antidepressant effects in subjects with bipolar depression.
Design: A randomized, placebo-controlled, doubleblind, crossover, add-on study conducted from October 2006 to June 2009.
Setting: Mood Disorders Research Unit at the National Institute of Mental Health, Bethesda, Maryland.
Patients: Eighteen subjects with DSM-IV bipolar depression (treatment-resistant).
Interventions: Subjects maintained at therapeutic levels of lithium or valproate received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days 2 weeks apart. The Montgomery- Asberg Depression Rating Scale was used to rate subjects at baseline and at 40, 80, 110, and 230 minutes and on days 1, 2, 3, 7, 10, and 14 postinfusion.
Results: Within 40 minutes, depressive symptoms significantly improved in subjects receiving ketamine compared with placebo (d=0.52, 95% confidence interval [CI], 0.28-0.76); this improvement remained significant through day 3. The drug difference effect size was largest at day 2 (d=0.80, 95% CI, 0.55-1.04). Seventy-one percent of subjects responded to ketamine and 6% responded to placebo at some point during the trial. One subject receiving ketamine and 1 receiving placebo developed manic symptoms. Ketamine was generally well tolerated; the most common adverse effect was dissociative symptoms, only at the 40-minute point.
Diazgranados, N., Ibrahim, L. Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., … Zarate Jr., Z. A. (2010). A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Archives of General Psychiatry, 67(8). http://dx.doi.org/10.1001/archgenpsychiatry.2010.90
Link to full text
What does the brain do during “soul journeys”? How do shamans alter consciousness and why is this important for healing? Are shamans different from other kinds of healers? Is there a connection between the rituals performed by chimpanzees and traditional shamanistic practices? All of these questions-and many more-are answered in Shamanism, Second Edition: A Biopsychosocial Paradigm of Consciousness and Healing. This text contains crosscultural examinations of the nature of shamanism, biological perspectives on alterations of consciousness, mechanisms of shamanistic healing, as well as the evolutionary origins of shamanism. It presents the shamanic paradigm within a biopsychosocial framework for explaining successful human evolution through group rituals. In the final chapter,”the author compares shamanistic rituals with chimpanzee displays to identify homologies that point to the ritual dynamics of our ancient hominid ancestors.
LSD has a controversial and extraordinary reputation, due to the special effects it can induce on human consciousness. Its experimental use lead to some groundbreaking discoveries about the brain and the deeper layers of the human psyche. After its application in neuroscience, and as a tool within psychotherapy, it was increasingly used by laymen for producing euphoria and religious experiences. Today, there is a resurgence of interest in LSD, including its possible uses in psychotherapy and for the treatment of some headache disorders. This book represents the first ever comprehensive review of the psychological and pharmacological effects of LSD. It draws on data from more than 3000 experimental and clinical studies. The Pharmacology of LSD provides a unique and valuable resource for anyone interested in better understanding this controversial hallucinogenic drug – including brain scientists, psychopharmacologists, addiction researchers, and psychiatrists.